Related Experiment Video
Updated: Jul 1, 2026
13:24
Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
Published on: April 11, 2016
Use of plasmid-derived external quality control samples in pharmacogenetic testing
Tahar van der Straaten1, Jesse Swen, Renee Baak-Pablo
1Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, PO Box 9600 2300 RA Leiden, The Netherlands. vanderstra@lumc.nl
Pharmacogenomics
|September 11, 2008
Summary
Implementing quality control in pharmacogenetic testing is crucial for reliable patient care. This study developed plasmid-derived controls to improve the accuracy of genetic variation analysis in clinical settings.
Area of Science:
- Pharmacogenetics
- Clinical Pharmacology
- Genetics
Background:
- Genetic variations in drug-metabolizing enzymes and targets significantly impact drug response.
- Pharmacogenetics is transitioning from research to routine clinical application.
- Reliable genotyping methods are essential for clinical pharmacogenetics.
Purpose of the Study:
- To assess the current state of quality control in pharmacogenetic studies.
- To develop and implement novel quality control materials for pharmacogenetic testing.
Main Methods:
- A survey of pharmacogenetic association studies published between 2005-2007 was conducted.
- The study involved the development of 12 plasmid-derived external controls.
- These controls were applied to pharmacogenetic testing.
Main Results:
- A minority of published studies reported quality control measures, with no standardized procedures identified.
- The developed plasmid-derived external controls were successfully implemented in pharmacogenetic testing.
- The initiative established 12 novel quality control materials.
Conclusions:
- There is a clear need for standardized quality control materials in pharmacogenetics.
- The developed plasmid-derived controls aim to enhance the quality of pharmacogenetic genotyping.
- These controls support both research and routine clinical applications of pharmacogenetics.
Related Concept Videos
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
01:29Pharmacogenetics and Pharmacogenomics: Overview
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...